Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PPID | Q08752 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4237428 | 0.84 | MMEL1 (0.48) | MMEL1MMP8MMETP53HPGD | |
| SCHEMBL4848732 | 0.82 | PPID (0.52) | ALDH1A1SMN1; SMN2MMEL1MMP8PPID | |
| SCHEMBL9488182 | 0.80 | TP53 (0.59) | ALDH1A1HTTNCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL9488184 | 0.80 | TP53 (0.59) | ALDH1A1HTTNCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL8442456 | 0.80 | CYP3A4 (0.48) | MMEL1MMP8MME | |
| SCHEMBL16232045 | 0.80 | ATM (0.62) | ALDH1A1 | |
| SCHEMBL1912540 | 0.79 | MME (0.66) | MMEL1MME | |
| SCHEMBL1912537 | 0.79 | MME (0.66) | MMEL1MME | |
| SCHEMBL27183269 | 0.79 | MMP8 (0.46) | MMEL1MMP8MME | |
| SCHEMBL12999389 | 0.78 | MMEL1 (0.53) | MMEL1MMP8MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
| EP-2438037-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139481-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | ALDH1A1 3645/4885HTT 106/4885NCOA1 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.